Subscribe to RSS
DOI: 10.1055/s-0031-1286104
© Georg Thieme Verlag KG Stuttgart · New York
Helicobacter pylori: Infektion mit lokalen Komplikationen und systemischen Auswirkungen
Helicobacter pylori: an infection with local complications and systemic effectsPublication History
eingereicht: 27.6.2011
akzeptiert: 18.8.2011
Publication Date:
31 August 2011 (online)

Schlüsselwörter
Helicobacter pylori - Prävention des Magenkarzinoms - extragastrale Erkrankungen - idiopathische thrombozytopenische Pupura
Keywords
Helicobacter pylori - prevention of gastric cancer - extragastric diseases - idiopathic thrombozytopenic purpura
Literatur
- 1
Gastric cancer and Helicobacter
pylori: a combined analysis of 12 case control studies nested within
prospective cohorts.
Gut.
2001;
49
347-353
MissingFormLabel
- 2
Abdullahi M, Annibale B, Capoccia D. et al .
The eradication of Helicobacter pylori
is affected by body mass index (BMI).
Obes Surg.
2008;
18
1450-1454
MissingFormLabel
- 3
Anderson H R.
Prevalence of asthma.
BMJ.
2005;
330
1037-1028
MissingFormLabel
- 4
Arnold D M, Bernotas A, Nazi I. et al .
Platelet count response to H. pylori treatment
in patients with immune thrombocytopenic purpura with and without
H. pylori infection.
Haematologica.
2009;
94
850-856
MissingFormLabel
- 5
Arslan E, Atilgan H, Yavasoglu I.
The prevalence of Helicobacter pylori in obese subjects.
Eur
J Intern Med.
2009;
20
695-697
MissingFormLabel
- 6
Asaka M, Kato M, Takahashi S. et
al .
Guidelines for the management of Helicobacter pylori
infection in Japan: 2009 revised edition.
Helicobacter.
2010;
15
1-20
MissingFormLabel
- 7
Bago J, Majstorovic K, Belosic-Halle Z. et al .
Antimicrobial resistance of H. pylori to
the outcome of 10-days vs. 7-days moxifloxacin based therapy for
the eradication.
Ann Clin Microbiol Antimicrob.
2010;
9
13
MissingFormLabel
- 8
Blaser M J, Chen Y, Reibman J.
Does Helicobacter pylori protect against asthma and allergy?.
Gut.
2008;
57
561-567
MissingFormLabel
- 9
Bornschein J, Selgrad M, Warnecke M. et al .
H. pylori infection is a key risk factor
for proximal gastric cancer.
Dig Dis Sci.
2010;
55
3124-3131
MissingFormLabel
- 10
Bourke B, Ceponis P, Chiba N. et al .
Canadian Helicobacter Study Group Consensus
Conference: Update on the approach to Helicobacter pylori infection
in children and adolescents – an evidence-based evaluation.
Can J Gastroenterol.
2005;
19
399-408
MissingFormLabel
- 11
Caselli M, Zullo A, Maconi G. et al .
„Cervia II Working Group Report 2006”:
guidelines on diagnosis and treatment of Helicobacter pylori infection
in Italy.
Dig Liver Dis.
2007;
39
782-789
MissingFormLabel
- 12
Cassaro M, Rugge M, Gutierrez O. et al .
Topographic patterns of intestinal metaplasia
and gastric cancer.
Am J Gastroenterol.
2000;
95
1431-1438
MissingFormLabel
- 13
Chey W D, Wong B C.
American College
of Gastroenterology guideline on the management of Helicobacter
pylori infection.
Am J Gastroenterol.
2007;
102
1808-2185
MissingFormLabel
- 14
Codolo G, Mazzi P, Amedei A. et al .
The neutrophil-activating protein of Helicobacter
pylori down-modulates Th2 inflammation in ovalbumin-induced allergic
asthma.
Cell Microbiol.
2008;
10
2355-2363
MissingFormLabel
- 15
D’Elios M M, Codolo G, Amedei A. et al .
Helicobacter pylori, asthma
and allergy.
FEMS Immunol Med Microbiol.
2009;
56
1-8
MissingFormLabel
- 16
de Vries A C, Kuipers E J.
Helicobacter
pylori infection and nonmalignant diseases.
Helicobacter.
2010;
15 Suppl 1
29-33
MissingFormLabel
- 17
de Vries A C, Kuipers E J, Rauws E A.
Helicobacter pylori eradication and gastric
cancer: when is the horse out of the barn?.
Am J Gastroenterol.
2009;
104
1342-1345
MissingFormLabel
- 18
de Vries A C, van Grieken N C, Looman C W. et al .
Gastric cancer
risk in patients with premalignant gastric lesions: a nationwide
cohort study in the Netherlands.
Gastroenterology.
2008;
134
945-952
MissingFormLabel
- 19
MF, Cavallaro L G, Scarpignato C.
‘Rescue’ therapies for the management of Helicobacter
pylori infection.
Dig Dis.
2006;
24
113-130
MissingFormLabel
- 20
Dore M P, Graham D Y, Mele R. et al .
Colloidal bismuth subcitrate-based twice-a-day
quadruple therapy as primary or salvage therapy for Helicobacter
pylori infection.
Am J Gastroenterol.
2002;
97
857-860
MissingFormLabel
- 21
Ekstrom A M, Held M, Hansson L E. et al .
Helicobacter pylori in gastric cancer established
by CagA immunoblot as a marker of past infection.
Gastroenterology.
2001;
121
784-791
MissingFormLabel
- 22
Essa A S, Kramer J R, Graham D Y. et al .
Meta-analysis: four-drug,
three-antibiotic, non-bismuth-containing „concomitant therapy” versus
triple therapy for Helicobacter pylori eradication.
Helicobacter.
2009;
14
109-118
MissingFormLabel
- 23
Ferrara M, Capozzi L, Russo R.
Effect of Helicobacter pylori eradication on platelet count
in children with chronic idiopathic thrombocytopenic purpura.
Hematology.
2009;
14
282-285
MissingFormLabel
- 24
Fischbach W, Malfertheiner P, Hoffmann J C. et al .
S3-guideline „helicobacter
pylori and gastroduodenal ulcer disease” of the German
society for digestive and metabolic diseases (DGVS) in cooperation
with the German society for hygiene and microbiology, society for
pediatric gastroenterology and nutrition e. V., German society for
rheumatology, AWMF-registration-no. 021 / 001.
Z
Gastroenterol.
2009;
47
1230-1263
MissingFormLabel
- 25
Fock K M, Katelaris P, Sugano K. et al .
Second Asia-Pacific Consensus Guidelines
for Helicobacter pylori infection.
J Gastroenterol Hepatol.
2009;
24
1587-600
MissingFormLabel
- 26
Fuccio L, Minardi M E, Zagari R M. et al .
Meta-analysis: duration
of first-line proton-pump inhibitor based triple therapy for Helicobacter
pylori eradication.
Ann Intern Med.
2007;
147
553-562
MissingFormLabel
- 27
Fuccio L, Zagari R M, Eusebi L H. et al .
Meta-analysis: can Helicobacter
pylori eradication treatment reduce the risk for gastric cancer?.
Ann Intern Med.
2009;
151
121-128
MissingFormLabel
- 28
Fukase K, Kato M, Kikuchi S. et al .
Effect of eradication of Helicobacter pylori
on incidence of metachronous gastric carcinoma after endoscopic resection
of early gastric cancer: an open-label, randomised controlled trial.
Lancet.
2008;
372
392-397
MissingFormLabel
- 29
Gasbarrini A, Franceschi F, Tartaglione R. et al .
Regression of autoimmune thrombocytopenia
after eradication of Helicobacter pylori.
Lancet.
1998;
352
878
MissingFormLabel
- 30
Gatta L, Vakil N, Leandro G. et
al .
Sequential therapy or triple therapy for Helicobacter
pylori infection: systematic review and meta-analysis of randomized
controlled trials in adults and children.
Am J Gastroenterol.
2009;
104
3069-3079
MissingFormLabel
- 31
Gene E, Calvet X, Azagra R. et
al .
Triple vs quadruple therapy for treating Helicobacter
pylori infection: an updated meta-analysis.
Aliment Pharmacol
Ther.
2003;
18
543-544
MissingFormLabel
- 32
Huang X, Qu X, Yan W. et
al .
Iron deficiency anaemia can be improved after eradication
of Helicobacter pylori.
Postgrad Med J.
2010;
86
272-278
MissingFormLabel
- 33
Kamada T, Hata J, Sugiu K. et
al .
Clinical features of gastric cancer discovered
after successful eradication of Helicobacter pylori: results from
a 9-year prospective follow-up study in Japan.
Aliment
Pharmacol Ther.
2005;
21
1121-1126
MissingFormLabel
- 34
Karlsson E A, Beck M A.
The burden of
obesity on infectious disease.
Exp Biol Med.
2010;
235
1412-1424
MissingFormLabel
- 35
Kodama M, Kitadai Y, Ito M. et
al .
Immune response to CagA protein is associated with
improved platelet count after Helicobacter pylori eradication in
patients with idiopathic thrombocytopenic purpura.
Helicobacter.
2007;
12
36-42
MissingFormLabel
- 36
Liou J M, Lin J T, Chang C Y. et al .
Levofloxacin-based and clarithromycin-based
triple therapies as first-line and second-line treatments for Helicobacter
pylori infection: a randomised comparative trial with crossover
design.
Gut.
2010;
59
572-578
MissingFormLabel
- 37
Mahachai V, Sirimontaporn N, Tumwasorn S. et al .
Sequential therapy in clarithromycin-sensitive
and -resistant Helicobacter pylori based on polymerase chain reaction
molecular test.
J Gastroenterol Hepatol.
2011;
26
825-828
MissingFormLabel
- 38
Malfertheiner P, Bazzoli F, Delchier J C. et al .
Helicobacter pylori eradication with a
capsule containing bismuth subcitrate potassium, metronidazole,
and tetracycline given with omeprazole versus clarithromycin-based
triple therapy.
Lancet.
2011;
377
905-913
MissingFormLabel
- 39
Malfertheiner P, Megraud F, O’Morain C. et al .
Current concepts in the management of Helicobacter
pylori infection: the Maastricht III Consensus Report.
Gut.
2007;
56
772-781
MissingFormLabel
- 40
Malfertheiner P, Selgrad M.
Helicobacter pylori
infection and current clinical areas of contention.
Curr
Opin Gastroenterol.
2010;
26
618-623
MissingFormLabel
- 41
Malfertheiner P, Sipponen P, Naumann M. et al .
Helicobacter pylori eradication has the
potential to prevent gastric cancer: a state-of-the-art critique.
Am J Gastroenterol.
2005;
100
2100-2115
MissingFormLabel
- 42
Megraud F.
Helicobacter pylori and antibiotic resistance.
Gut.
2007;
56
1502
MissingFormLabel
- 43
Moayyedi P.
Should triple therapy for Helicobacter pylori eradication be prescribed
for 1 week or 2 weeks?.
Nat Clin Pract Gastroenterol Hepatol.
2007;
4
596-597
MissingFormLabel
- 44
Nista E C, Candelli M, Zocco M A. et al .
Moxifloxacin-based strategies for first-line
treatment of Helicobacter pylori infection.
Aliment Pharmacol Ther.
2005;
21
1241-1247
MissingFormLabel
- 45
Ohkusa T, Fujiki K, Takashimizu I. et al .
Improvement in atrophic gastritis and intestinal
metaplasia in patients in whom Helicobacter pylori was eradicated.
Ann Intern Med.
2001;
134
380-386
MissingFormLabel
- 46
Robinson K, Kenefeck R, Pidgeon E L. et al .
Helicobacter pylori-induced peptic ulcer
disease is associated with inadequate regulatory T cell responses.
Gut.
2008;
57
1375-1385
MissingFormLabel
- 47
Romano M, Cuomo A, Gravina A G. et al .
Empirical levofloxacin-containing versus
clarithromycin-containing sequential therapy for Helicobacter pylori
eradication.
Gut.
2010;
59
1465-1470
MissingFormLabel
- 48
Rugge M, Meggio A, Pennelli G. et
al .
Gastritis staging in clinical practice: the OLGA
staging system.
Gut.
2007;
56
631-636
MissingFormLabel
- 49
Sarker S A, Mahmud H, Davidsson L. et al .
Causal relationship of Helicobacter pylori
with iron-deficiency anemia or failure of iron supplementation in
children.
Gastroenterology.
2008;
135
1534-1542
MissingFormLabel
- 50
Strachan D P.
Hay fever, hygiene, and household size.
BMJ.
1989;
299
1259-1260
MissingFormLabel
- 51
Suzuki T, Matsuo K, Ito H. et
al .
Smoking increases the treatment failure for Helicobacter
pylori eradication.
Am J Med.
2006;
119
217-224
MissingFormLabel
- 52
Take S, Mizuno M, Ishiki K. et
al .
Baseline gastric mucosal atrophy is a risk factor
associated with the development of gastric cancer after Helicobacter
pylori eradication therapy in patients with peptic ulcer diseases.
J Gastroenterol.
2007;
42 Suppl
17
21-27
MissingFormLabel
- 53
Uemura N, Mukai T, Okamoto S. et al .
Effect of Helicobacter pylori eradication
on subsequent development of cancer after endoscopic resection of
early gastric cancer.
Cancer Epidemiol Biomarkers Prev.
1997;
6
639-642
MissingFormLabel
- 54
Uemura N, Okamoto S, Yamamoto S. et al .
Helicobacter pylori infection and the development
of gastric cancer.
N Engl J Med.
2001;
345
784-789
MissingFormLabel
- 55
Weigt J, Malfertheiner P.
Influence of Helicobacter
pylori on gastric regulation of food intake.
Curr Opin
Clin Nutr Metab Care.
2009;
12
522-525
MissingFormLabel
- 56
Wong B C, Lam S K, Wong W M. et al .
Helicobacter pylori eradication
to prevent gastric cancer in a high-risk region of China.
JAMA.
2004;
291
187-194
MissingFormLabel
- 57
Wu D C, Hsu P I, Wu J Y. et al .
Sequential and concomitant therapy with four
drugs is equally effective for eradication of H pylori infection.
Clin Gastroenterol Hepatol.
2010;
8
36-41
MissingFormLabel
Prof. Dr. Dres. h. c. Peter Malfertheiner
Klinik für
Gastroenterologie, Hepatologie und Infektiologie
Otto-von-Guericke-Universität
Leipziger Str. 44
39120 Magdeburg
Phone: 0391/6713100
Fax: 0391/6713105
Email: peter.malfertheiner@med.ovgu.de